Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.
Journal: Journal of hematology & oncology
Published: April 19, 2022
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Journal: Cancers
Published: December 21, 2021
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 11, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 20, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Journal: Journal of hematology & oncology
Published: April 20, 2021
Socioeconomic Factors and Survival of Multiple Myeloma Patients.
Journal: Cancers
Published: November 27, 2020
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
Journal: Leukemia & lymphoma
Published: July 09, 2019
Refractory inflammatory myopathy in hematopoietic stem cell transplant patients with chronic graft-versus-host disease: report of two cases.
Journal: Hematology, transfusion and cell therapy
Published: December 20, 2018
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
Journal: Journal of hematology & oncology
Published: September 28, 2018
A case of neurocognitive deficit strongly related to dasatinib therapy.
Journal: Hematology, transfusion and cell therapy
Published: August 17, 2018
Last Updated: 09/26/2026